What New Research Says About Menopause and Heart Disease, Including a Blood Test Most Women Have Never Been Offered
Heart disease is the leading cause of death in women, per the CDC, and the risk climbs sharply after menopause. For decades, doctors blamed estrogen loss. That’s part of the story, but two new studies are reshaping what we actually know.
A Virginia Tech review suggests menopause rewires the heart’s gene-regulation system itself. A Penn State reanalysis of Women’s Health Initiative data found that hormone therapy meaningfully improved several cardiovascular markers, including one most women have never been tested for.
If you’ve been following the broader conversation around women’s hormones and health, these findings add critical new context.
Why Menopause Raises Heart Disease Risk in the First Place
After menopause, women see shifts in cholesterol, blood pressure, body composition and insulin sensitivity, all of which drive cardiovascular disease. A February 2026 AHA scientific statement projected that nearly 6 in 10 U.S. women will have some form of cardiovascular disease by 2050, driven by rising rates of high blood pressure, diabetes and obesity. The new research suggests the biological reasons run deeper than the hormone itself.
What the Virginia Tech Epigenetics Study Found
The March 2026 review in Cells, led by Sumita Mishra at the Fralin Biomedical Research Institute, examined how estrogen loss alters the epigenome, the system of biological switches that controls which genes turn on and off inside cells.
The finding is significant because epigenetic changes can persist even after the original trigger, in this case estrogen loss, is gone. That may help explain why cardiovascular risk continues climbing in the years after menopause, not just at the moment of transition.
This kind of mechanism has been studied extensively in breast cancer but was largely unexplored in heart tissue until now. Related Mishra lab work published in Hypertension examined how estrogen-dependent signaling in the heart and blood vessels shifts after menopause, contributing to changes in vascular function.
The study also flags HFpEF, heart failure with preserved ejection fraction, as a growing concern since the condition disproportionately affects women and becomes more common after menopause. Because diet, exercise, metabolic disease and genetic predisposition all interact with these epigenetic pathways, hormone therapy alone cannot fully address the risk.
What the Penn State WHI Reanalysis Found About HRT and Heart Health
The April 2025 study in Obstetrics and Gynecology, led by Matthew Nudy at Penn State College of Medicine, tracked 2,696 WHI participants over six years. Both hormone therapy formulations reduced LDL cholesterol by approximately 11%, raised HDL, lowered total cholesterol and improved insulin resistance.
The most significant finding involved lipoprotein(a), a genetic risk marker for heart attack and stroke that most women have never been tested for and that isn’t reduced by diet, exercise or most medications. Hormone therapy lowered it. The reduction was more pronounced in participants with American Indian, Alaska Native, Asian or Pacific Islander ancestry, at 41% and 38% respectively.
Hormone therapy isn’t a heart disease treatment and isn’t right for everyone, but these findings push back against the idea it offers no cardiovascular benefit.
What Lipoprotein(a) Is and Why Women Should Know About It
Lipoprotein(a), or Lp(a), is a fatty particle in the blood that raises heart attack and stroke risk independently of LDL cholesterol. Unlike LDL, Lp(a) levels are largely determined by genetics and don’t respond to lifestyle changes or most medications. Cardiology groups increasingly recommend at least one Lp(a) test in a lifetime to identify hidden genetic risk, particularly for women with a family history of early heart disease.
The Timing Hypothesis and What Women Can Do Now
The Penn State findings reinforce the timing hypothesis: cardiovascular benefits from HRT appear most significant when started within 10 years of menopause or before age 60. Any decision should involve a clinician familiar with a patient’s full cardiovascular and breast cancer risk profile.
Beyond HRT, the epigenetic research is a reminder that daily habits compound over time. Knowing your numbers, specifically blood pressure, LDL, HDL, triglycerides, fasting glucose and if appropriate Lp(a), gives clinicians the clearest picture of where risk actually sits.
For women approaching menopause with significant symptoms, the conversation about hormone therapy is worth having with current evidence rather than the 20-year-old data that still shapes much of the surrounding fear.
This article was created by content specialists using various tools, including AI.
